EDIT
NASDAQ · Biotechnology
Editas Medicine Inc
$2.75
+0.18 (+7.00%)
Open$2.64
Previous Close$2.57
Day High$3.01
Day Low$2.51
52W High$3.94
52W Low$1.66
Volume—
Avg Volume2.27M
Market Cap389.33M
P/E Ratio—
EPS$-0.74
SectorBiotechnology
Analyst Ratings
Buy
19 analysts
Price Target
+365.8% upside
Current
$2.75
$2.75
Target
$12.81
$12.81
$8.62
$12.81 avg
$14.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 68.37M | 53.77M | 30.54M |
| Net Income | -270,072,021 | -191,163,837 | 4.38M |
| Profit Margin | -395.0% | -375.3% | 14.4% |
| EBITDA | -261,087,589 | -195,071,340 | 9.59M |
| Free Cash Flow | — | — | 5.15M |
| Rev Growth | +27.2% | +27.2% | +16.6% |
| Debt/Equity | 2.15 | 2.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |